Development of a monoclonal antibody to urinary degradation                products from the C-terminal telopeptide alpha 1 chain of type                I collagen. Application in an enzyme Immunoassay and                comparison to CrossLaps(TM) ELISA.

Fledelius C; Kolding I; Quist P; Bonde M; Hassager C; Reginster JY; Jørn Hejgaard; Hanne Frøkiær

Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA.

Fledelius C, Kolding I, Quist P, Bonde M, Hassager C, Reginster JY, Jørn Hejgaard, Hanne Frøkiær

Osteometer BioTech A/S

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

A monoclonal antibody MAbA7 was raised against a synthetic peptide having a sequence (EKAHDGGR) specific for a part of the C-telopeptide alpha 1 chain of type I collagen. MAbA7 was labelled with horseradish peroxide and used in a competitive one-step enzyme-linked immunosorbent assay (ELISA) for measurement of urinary type I collagen degradation products. The assay was technically evaluated and preliminary clinical data are presented. The measuring range was 200-7000 mu g l(-1) with a detection limit of 25 mu g l(-1). Within-run and total CVs were 5.5 and 8.0%, respectively. Analytical recovery averaged 96.6%+/-5.3 (mean+/-1SD). Values obtained in the ELISA were highly correlated (r=0.93) to values obtained by a commercially available assay (CrossLaps(TM) ELISA) known to measure urinary degradation products derived from the C-telopeptide of type I collagen reflecting the rate of bone resorption. Investigation of the urinary fragments responsible for the immunological response in the two assays revealed, however, that they are not identical. Values obtained in urine samples from postmenopausal women (n=108) and patients with Paget's disease (n=6) increased 43% (p<0.01) and 28-fold (p<0.001), respectively, when compared to a premenopausal level (n=50). A decrease in the urinary concentrations of 67% (p<0.01) was seen after 6 months in urine samples from postmenopausal women (n=13) receiving hormone replacement therapy (HRT) compared to a group receiving placebo (n=9). Likewise, the urinary concentrations decreased 88% (p<0.001) in early postmenopausal women receiving bisphosphonate therapy (n=11) for a period of 9 months compared to a group receiving placebo (n=12). These results suggest that the monoclonal antibody and the new assay may be useful for further investigations of the physiological and clinical importance of type I collagen degradation.

Original language	English
Journal	Scandinavian Journal of Clinical & Laboratory Investigation
Volume	57
Issue number	1
Pages (from-to)	73-83
ISSN	0036-5513
Publication status	Published - 1997

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA.'. Together they form a unique fingerprint.

Cite this

C, F., I, K., P, Q., M, B., C, H., JY, R., Hejgaard, J., & Frøkiær, H. (1997). Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA. Scandinavian Journal of Clinical & Laboratory Investigation, 57(1), 73-83.

C, Fledelius ; I, Kolding ; P, Quist et al. / Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA. In: Scandinavian Journal of Clinical & Laboratory Investigation. 1997 ; Vol. 57, No. 1. pp. 73-83.

@article{76148cc7f30b40c5b188e155505f37ea,

title = "Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA.",

abstract = "A monoclonal antibody MAbA7 was raised against a synthetic peptide having a sequence (EKAHDGGR) specific for a part of the C-telopeptide alpha 1 chain of type I collagen. MAbA7 was labelled with horseradish peroxide and used in a competitive one-step enzyme-linked immunosorbent assay (ELISA) for measurement of urinary type I collagen degradation products. The assay was technically evaluated and preliminary clinical data are presented. The measuring range was 200-7000 mu g l(-1) with a detection limit of 25 mu g l(-1). Within-run and total CVs were 5.5 and 8.0%, respectively. Analytical recovery averaged 96.6%+/-5.3 (mean+/-1SD). Values obtained in the ELISA were highly correlated (r=0.93) to values obtained by a commercially available assay (CrossLaps(TM) ELISA) known to measure urinary degradation products derived from the C-telopeptide of type I collagen reflecting the rate of bone resorption. Investigation of the urinary fragments responsible for the immunological response in the two assays revealed, however, that they are not identical. Values obtained in urine samples from postmenopausal women (n=108) and patients with Paget's disease (n=6) increased 43% (p<0.01) and 28-fold (p<0.001), respectively, when compared to a premenopausal level (n=50). A decrease in the urinary concentrations of 67% (p<0.01) was seen after 6 months in urine samples from postmenopausal women (n=13) receiving hormone replacement therapy (HRT) compared to a group receiving placebo (n=9). Likewise, the urinary concentrations decreased 88% (p<0.001) in early postmenopausal women receiving bisphosphonate therapy (n=11) for a period of 9 months compared to a group receiving placebo (n=12). These results suggest that the monoclonal antibody and the new assay may be useful for further investigations of the physiological and clinical importance of type I collagen degradation. ",

author = "Fledelius C and Kolding I and Quist P and Bonde M and Hassager C and Reginster JY and J{\o}rn Hejgaard and Hanne Fr{\o}ki{\ae}r",

year = "1997",

language = "English",

volume = "57",

pages = "73--83",

journal = "Scandinavian Journal of Clinical & Laboratory Investigation",

issn = "0036-5513",

publisher = "CRC Press/Balkema",

number = "1",

}

C, F, I, K, P, Q, M, B, C, H, JY, R, Hejgaard, J & Frøkiær, H 1997, 'Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA.', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 57, no. 1, pp. 73-83.

Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA. / C, Fledelius; I, Kolding; P, Quist et al.
In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 57, No. 1, 1997, p. 73-83.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA.

AU - C, Fledelius

AU - I, Kolding

AU - P, Quist

AU - M, Bonde

AU - C, Hassager

AU - JY, Reginster

AU - Hejgaard, Jørn

AU - Frøkiær, Hanne

PY - 1997

Y1 - 1997

N2 - A monoclonal antibody MAbA7 was raised against a synthetic peptide having a sequence (EKAHDGGR) specific for a part of the C-telopeptide alpha 1 chain of type I collagen. MAbA7 was labelled with horseradish peroxide and used in a competitive one-step enzyme-linked immunosorbent assay (ELISA) for measurement of urinary type I collagen degradation products. The assay was technically evaluated and preliminary clinical data are presented. The measuring range was 200-7000 mu g l(-1) with a detection limit of 25 mu g l(-1). Within-run and total CVs were 5.5 and 8.0%, respectively. Analytical recovery averaged 96.6%+/-5.3 (mean+/-1SD). Values obtained in the ELISA were highly correlated (r=0.93) to values obtained by a commercially available assay (CrossLaps(TM) ELISA) known to measure urinary degradation products derived from the C-telopeptide of type I collagen reflecting the rate of bone resorption. Investigation of the urinary fragments responsible for the immunological response in the two assays revealed, however, that they are not identical. Values obtained in urine samples from postmenopausal women (n=108) and patients with Paget's disease (n=6) increased 43% (p<0.01) and 28-fold (p<0.001), respectively, when compared to a premenopausal level (n=50). A decrease in the urinary concentrations of 67% (p<0.01) was seen after 6 months in urine samples from postmenopausal women (n=13) receiving hormone replacement therapy (HRT) compared to a group receiving placebo (n=9). Likewise, the urinary concentrations decreased 88% (p<0.001) in early postmenopausal women receiving bisphosphonate therapy (n=11) for a period of 9 months compared to a group receiving placebo (n=12). These results suggest that the monoclonal antibody and the new assay may be useful for further investigations of the physiological and clinical importance of type I collagen degradation.

AB - A monoclonal antibody MAbA7 was raised against a synthetic peptide having a sequence (EKAHDGGR) specific for a part of the C-telopeptide alpha 1 chain of type I collagen. MAbA7 was labelled with horseradish peroxide and used in a competitive one-step enzyme-linked immunosorbent assay (ELISA) for measurement of urinary type I collagen degradation products. The assay was technically evaluated and preliminary clinical data are presented. The measuring range was 200-7000 mu g l(-1) with a detection limit of 25 mu g l(-1). Within-run and total CVs were 5.5 and 8.0%, respectively. Analytical recovery averaged 96.6%+/-5.3 (mean+/-1SD). Values obtained in the ELISA were highly correlated (r=0.93) to values obtained by a commercially available assay (CrossLaps(TM) ELISA) known to measure urinary degradation products derived from the C-telopeptide of type I collagen reflecting the rate of bone resorption. Investigation of the urinary fragments responsible for the immunological response in the two assays revealed, however, that they are not identical. Values obtained in urine samples from postmenopausal women (n=108) and patients with Paget's disease (n=6) increased 43% (p<0.01) and 28-fold (p<0.001), respectively, when compared to a premenopausal level (n=50). A decrease in the urinary concentrations of 67% (p<0.01) was seen after 6 months in urine samples from postmenopausal women (n=13) receiving hormone replacement therapy (HRT) compared to a group receiving placebo (n=9). Likewise, the urinary concentrations decreased 88% (p<0.001) in early postmenopausal women receiving bisphosphonate therapy (n=11) for a period of 9 months compared to a group receiving placebo (n=12). These results suggest that the monoclonal antibody and the new assay may be useful for further investigations of the physiological and clinical importance of type I collagen degradation.

M3 - Journal article

SN - 0036-5513

VL - 57

SP - 73

EP - 83

JO - Scandinavian Journal of Clinical & Laboratory Investigation

JF - Scandinavian Journal of Clinical & Laboratory Investigation

IS - 1

ER -

C F, I K, P Q, M B, C H, JY R et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme Immunoassay and comparison to CrossLaps(TM) ELISA. Scandinavian Journal of Clinical & Laboratory Investigation. 1997;57(1):73-83.